Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Hepion Pharmaceuticals Inc (HEPA)

Hepion Pharmaceuticals Inc (HEPA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 118,149
  • Shares Outstanding, K 76,225
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,350 K
  • 60-Month Beta 1.18
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.10
Trade HEPA with:

Options Overview Details

View History
  • Implied Volatility 160.14%
  • Historical Volatility 47.43%
  • IV Percentile 23%
  • IV Rank 18.85%
  • IV High 380.71% on 09/28/20
  • IV Low 108.90% on 10/20/20
  • Put/Call Vol Ratio 0.16
  • Today's Volume 790
  • Volume Avg (30-Day) 1,875
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 17,046
  • Open Int (30-Day) 25,049

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.19
  • Number of Estimates 1
  • High Estimate -0.19
  • Low Estimate -0.19
  • Prior Year -0.58
  • Growth Rate Est. (year over year) +67.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4983 +5.45%
on 09/22/21
1.8500 -14.59%
on 09/08/21
+0.0200 (+1.28%)
since 08/27/21
3-Month
1.3599 +16.19%
on 08/19/21
2.2700 -30.40%
on 06/28/21
-0.6800 (-30.09%)
since 06/25/21
52-Week
1.3599 +16.19%
on 08/19/21
3.6899 -57.18%
on 10/20/20
-1.4600 (-48.03%)
since 09/25/20

Most Recent Stories

More News
Additional Data from Hepion Pharmaceuticals' Phase 2a 'AMBITION' Trial Further Strengthens CRV431 Clinical Profile and Paves Way for Initiation of Phase 2b 'ASCEND-NASH' Clinical Program

-- Pro-C3 and ALT reductions point to anti-inflammatory and antifibrotic effects of CRV431

HEPA : 1.5800 (+1.94%)
Hepion Pharmaceuticals Schedules Conference Call to Review Data from Phase 2a 'AMBITION' Clinical Trial of CRV431 in NASH

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis...

HEPA : 1.5800 (+1.94%)
Hepion Pharmaceuticals Announces Postponement of 2021 Annual Meeting of Stockholders

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis...

HEPA : 1.5800 (+1.94%)
Thinking about buying stock in Verb Technology, Casper Sleep, Millendo Therapeutics, Lipocine, or Hepion Pharmaceuticals?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VERB, CSPR, TPST, LPCN, and HEPA.

LPCN : 1.1100 (+0.91%)
HEPA : 1.5800 (+1.94%)
TPST : 14.88 (+2.27%)
VERB : 1.8500 (+3.35%)
CSPR : 4.99 (+2.46%)
Hepion Pharmaceuticals Announces Positive Topline Data from Phase 2a 'AMBITION' NASH Trial; All Primary Endpoints Achieved

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis...

HEPA : 1.5800 (+1.94%)
Hepion Pharmaceuticals Announces Adjournment of Annual Meeting

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis...

HEPA : 1.5800 (+1.94%)
Hepion Pharmaceuticals to be Added to the Russell Microcap(R) Index

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, "Hepion"), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic...

HEPA : 1.5800 (+1.94%)
Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis...

HEPA : 1.5800 (+1.94%)
Hepion Pharmaceuticals Presents Machine Learning "Learn and Confirm" Modeling Strategy at 4th Global NASH Congress

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, "Hepion"), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI") - driven therapeutic drug development for the treatment of non-alcoholic...

HEPA : 1.5800 (+1.94%)
ENDRA Life Sciences Reports 2020 Fourth Quarter and Full Year Financial Results, Provides Business Update

NDRA : 1.7700 (-1.67%)
HEPA : 1.5800 (+1.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Hepion Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. It is focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis and chronic hepatitis virus infection. The Company's lead drug candidate CRV431, reduces liver fibrosis and hepatocellular...

See More

Key Turning Points

3rd Resistance Point 1.7433
2nd Resistance Point 1.6867
1st Resistance Point 1.6333
Last Price 1.5800
1st Support Level 1.5233
2nd Support Level 1.4667
3rd Support Level 1.4133

See More

52-Week High 3.6899
Fibonacci 61.8% 2.7998
Fibonacci 50% 2.5249
Fibonacci 38.2% 2.2500
Last Price 1.5800
52-Week Low 1.3599

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar